FDA refuses to file Novo Nordisk application

Novo Nordisk has received a Refusal to File letter from the US Food and Drug Administration (FDA) for its application for a version of Ozempic, which Novo Nordisk announces on Monday evening.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app